Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
McKinsey
Moodys
Citi
Express Scripts
Fuji
Chinese Patent Office
Baxter
Chubb
Deloitte

Generated: August 16, 2017

DrugPatentWatch Database Preview

NUPLAZID Drug Profile

« Back to Dashboard

Which patents cover Nuplazid, and when can generic versions of Nuplazid launch?

Nuplazid is a drug marketed by Acadia Pharms Inc and is included in one NDA. There are thirteen patents protecting this drug.

This drug has one hundred and twenty-nine patent family members in twenty-seven countries.

The generic ingredient in NUPLAZID is pimavanserin tartrate. One supplier is listed for this compound. Additional details are available on the pimavanserin tartrate profile page.

Summary for Tradename: NUPLAZID

Patents:13
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Drug Prices:see details
DailyMed Link:NUPLAZID at DailyMed

Pharmacology for Tradename: NUPLAZID

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Acadia Pharms Inc
NUPLAZID
pimavanserin tartrate
TABLET;ORAL207318-001Apr 29, 2016RXYesYes► Subscribe► SubscribeYY ► Subscribe
Acadia Pharms Inc
NUPLAZID
pimavanserin tartrate
TABLET;ORAL207318-001Apr 29, 2016RXYesYes► Subscribe► SubscribeYY ► Subscribe
Acadia Pharms Inc
NUPLAZID
pimavanserin tartrate
TABLET;ORAL207318-001Apr 29, 2016RXYesYes► Subscribe► SubscribeYY ► Subscribe
Acadia Pharms Inc
NUPLAZID
pimavanserin tartrate
TABLET;ORAL207318-001Apr 29, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
Acadia Pharms Inc
NUPLAZID
pimavanserin tartrate
TABLET;ORAL207318-001Apr 29, 2016RXYesYes► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: NUPLAZID

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,994,193Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases► Subscribe
7,868,176Salts of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-y1)-N'-(4-(2-methylprop- yloxy)phenylmethyl)carbamide and their preparation► Subscribe
2,017,165,273► Subscribe
8,008,323Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases► Subscribe
8,236,960Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: NUPLAZID

Country Document Number Estimated Expiration
Poland356365► Subscribe
Germany602004016288► Subscribe
Russian Federation2465267► Subscribe
Slovenia1794126► Subscribe
Russian Federation2002126554► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
McKinsey
Harvard Business School
UBS
Colorcon
McKesson
Cerilliant
Farmers Insurance
Boehringer Ingelheim
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot